

# PROVIDER QUICK POINTS

## PROVIDER INFORMATION



April 8, 2020

### MHCP Pharmacy Benefit Exclusion for Beovu<sup>®</sup>, Quzyttir<sup>™</sup>, Reblozyl<sup>®</sup>, Recarbrio<sup>™</sup>, Ruxience<sup>™</sup>, Truxima<sup>®</sup> and Zirabev<sup>®</sup>

Effective April 8, 2020, the drugs listed in the table below will be excluded from pharmacy benefit coverage due to clinician-administered route of administration and may be available for medical benefit coverage for subscribers who are eligible.

Drug Name (Generic Name)
Beovu <sup>®</sup> (brolucizumab-dblb)
Quzyttir <sup>™</sup> (cetirizine hydrochloride)
Reblozyl <sup>®</sup> (luspatercept-aamt)
Recarbrio <sup>™</sup> (imipenem, cilastatin, and relebactam)
Ruxience <sup>™</sup> (rituximab-pvvr)
Truxima <sup>®</sup> (rituximab-abbs)
Zirabev <sup>®</sup> (bevacizumab-bvzr)

### Products Impacted

This applies to the following Minnesota Health Care Programs:

- Families and Children [*formerly known as* Prepaid Medical Assistance Program (PMAP)]
- MinnesotaCare (MNCare)
- Minnesota Senior Care Plus (MSC+)

### Questions?

If you have questions for a member enrolled in a Minnesota Health Care Programs (MHCP) plan, please contact provider services at **1-866-518-8448**. Please contact provider services at **(651) 662-5200** or **1-800-262-0820** for all other questions.